Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients

Urea Cycle Disorders Clinical Trial

Official title:

Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05671666
• Other study ID #: Ureagenesis01352
• Status: Recruiting
• Phase: N/A
• Start date: October 31, 2019
• Est. completion date: December 31, 2035

Study information

• Verified date: January 2023
• Source: University Children's Hospital, Zurich
• Contact: Johannes Häberle
• Phone: 0041-442667342
• Email: Johannes.haeberle[@]kispi.uzh.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Urea cycle disorders (UCDs) are dramatic congenital inherited metabolic disorders. There is no cure. Many novel therapeutic approaches are currently being developed, which hopefully will change the current situation. Testing the efficacy of such new therapies in patients is a challenge, because many clinical parameters are influenced by several disturbances and biochemical parameters are often not very specific. The measurement of ureagenesis is a tool to analyze the entire function of the urea cycle in a single test. This is more meaningful for the characterization of UCD patients than the analysis of single metabolites or enzymes. Therefore, the test will be important to evaluate current and future novel therapies. The term "ureagenesis" means "production of urea", which is the main task of the urea cycle. This total urea production can be measured with a "tracer" (in this case a stable ammonium chloride isotope). This tracer is non-radioactive and non-toxic. It is for example used as an unmarked substance in cough syrup, diuretic drugs and as food additive. Thus, the tracer does not pose a risk to the participant, especially since only a very low dose is applied. The investigators will analyze specific substances from the urea cycle (namely [15N, 14N] urea and several [15N] amino acids) that are produced during the test and compare them with results from healthy people. The maximum test duration is 5 hours. This project is being carried out at one site, namely the University Children's Hospital in Zurich. This project is being carried out under Swiss law. The responsible Ethics Committee has reviewed and approved the study.

Description:

The term "we" was exchanged by "The investigators" as recommended.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2035
• Est. primary completion date: December 31, 2035
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• healthy subjects at any age and given written informed consent
• subjects with a UCD confirmed by genetic or enzymatic diagnostics at any age and given written informed consent

Exclusion Criteria:

• healthy subjects with acute and chronic disease requiring treatment of any kind
• pregnant or lactating women.
• UCD patients with acute and chronic (other than her/his UCD) disease requiring treatment
• UCD patients in which intake of carglumic acid cannot be stopped for 24 hours prior to the test

Related Conditions & MeSH terms

• Urea Cycle Disorders
• Urea Cycle Disorders, Inborn

Intervention

Diagnostic Test:
• Urea cycle flux study
Quantification of ureagenesis

Locations

Country	Name	City	State
Switzerland	University Children's Hospital	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University Children's Hospital, Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of flux through the urea cycle using stable isotopes in healthy subjects and patients, and the change of rate of flux through the urea cycle in patients after an intervention or for follow-up.	Measurement of total concentrations of urea in plasma (in mmol/L) and amino acids in plasma (in micromol/L) and their enrichment (in %) after application of a stable isotope tracer by using a high-resolution liquid chromatography mass spectrometry (LC MS) method.	Baseline for healthy subjects and patients and post-intervention (up to 1 year after the intervention) for patients